Prognostic Role of Serum IL-6 Levels in Bladder Cancer Patients and Hints of its Origin

URN to cite this document:: urn:nbn:de:bvb:355-epub-770236
DOI to cite this document:: 10.5283/epub.77023

Engelmann, Simon U.

; Pickl, Christoph ; Haas, Maximilian

; Kasparbauer, Felix

; Rinderknecht, Emily ; Kälble, Sebastian ; van Rhijn, Bas W. G. ; Siska, Peter J.

; Decking, Sonja-Maria ; Renner, Kathrin

; Pichler, Renate ; Burger, Maximilian ; Gužvić, Miodrag

; Mayr, Roman

License: Creative Commons Attribution 4.0
PDF - Published Version
(1MB)

Date of publication of this fulltext: 02 Jul 2025 10:20

Alternative links to fulltext:DOI Publisher

Details

Preview

Export bibliographical data

Abstract

Background Interleukin-6 (IL-6) is associated with adverse clinical outcome in cancer patients. In bladder cancer (BC) patients, higher IL-6 serum levels have been linked with adverse pathologic features, worse overall survival (OS) and cancer-specific survival (CSS). IL-6 is being investigated as a therapeutic target. However, concentrations in tumor-tissue are not investigated in detail. ...